<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: For patients with systemic <z:hpo ids='HP_0002633'>vasculitis</z:hpo> (SV) refractory to conventional therapy, new treatment strategies aimed at aggressive induction of remission and relapse prevention are being sought </plain></SENT>
<SENT sid="1" pm="."><plain>We herein report our single-centre experience in treating four patients with refractory SV employing non-myeloablative autologous haematopoietic stem cell transplantation (HSCT) </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Four patients with refractory SV (two with neurovascular <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet disease</z:e>, one with neurovascular <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjögren</z:e> syndrome, and one with Wegener <z:hpo ids='HP_0002955'>granulomatosis</z:hpo>) were involved in an Institutional Review Board (IRB) and US Food and Drug Administration (FDA) approved phase I clinical trial of high dose chemotherapy and autologous HSCT </plain></SENT>
<SENT sid="3" pm="."><plain>Peripheral blood stem cells were mobilised with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (Cy) and granulocyte-colony stimulating factor (G-CSF) </plain></SENT>
<SENT sid="4" pm="."><plain>Conditioning regimen consisted of Cy 200 mg/kg and rabbit anti-thymocyte globulin 5.5 mg/kg intravenously (iv) </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: <z:hpo ids='HP_0000001'>All</z:hpo> four patients tolerated HSCT well without transplant related mortality or any significant toxicity </plain></SENT>
<SENT sid="6" pm="."><plain>At median follow-up of 28 (range 22-36) months <z:hpo ids='HP_0000001'>all</z:hpo> patients were alive </plain></SENT>
<SENT sid="7" pm="."><plain>Three patients (one with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet disease</z:e>, one with <z:e sem="disease" ids="C1527336" disease_type="Disease or Syndrome" abbrv="">Sjögren</z:e> syndrome, and one with Wegener <z:hpo ids='HP_0002955'>granulomatosis</z:hpo>) entered a sustained remission at 6, 6 and 24 months, respectively, after transplant </plain></SENT>
<SENT sid="8" pm="."><plain>They had significant decrease in disease activity and disease or treatment related damage, as measured by the Birmingham <z:hpo ids='HP_0002633'>Vasculitis</z:hpo> Activity Score and <z:hpo ids='HP_0002633'>Vasculitis</z:hpo> Damage Index, respectively </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> three patients who achieved remission discontinued immunosuppressive therapy at the time of transplant and have not required treatment since </plain></SENT>
<SENT sid="10" pm="."><plain>One patient with <z:e sem="disease" ids="C0004943" disease_type="Disease or Syndrome" abbrv="">Behcet disease</z:e> and positive for human leukocyte antigen (HLA)-B51 has not improved after HSCT </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: We suggest non-myeloablative autologous HSCT is an alternative therapy for select patients with SV refractory to conventional immunosuppressive therapies </plain></SENT>
</text></document>